tiprankstipranks
Advertisement
Advertisement

VERA Stock Latest News

Vera Therapeutics price target lowered to $91 from $95 at Evercore ISI
The FlyVera Therapeutics price target lowered to $91 from $95 at Evercore ISI
7d ago
VERA
Analyst Reiterates Buy on Vera as Atacicept Progress and Strong Cash Position Support Unchanged $110 Price Target
PremiumRatings
Analyst Reiterates Buy on Vera as Atacicept Progress and Strong Cash Position Support Unchanged $110 Price Target
10d ago
VERA
Vera Therapeutics: Buy Rating Reiterated on Strong Atacicept Outlook and Launch Readiness; $73 Price Target Maintained
PremiumRatings
Vera Therapeutics: Buy Rating Reiterated on Strong Atacicept Outlook and Launch Readiness; $73 Price Target Maintained
14d ago
VERA
Vera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37)
PremiumThe Fly
Vera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37)
14d ago
VERA
Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
PremiumThe Fly
Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
2M ago
VERA
VRTX
Vertex poses ‘no threat’ to Vera Therapeutics’ atacicept, says BofA
PremiumThe FlyVertex poses ‘no threat’ to Vera Therapeutics’ atacicept, says BofA
2M ago
VERA
VRTX
Maintaining the Bull Case on Vera: Atacicept’s Competitive Edge and $2.2B IgAN Peak Sales Upside
Premium
Ratings
Maintaining the Bull Case on Vera: Atacicept’s Competitive Edge and $2.2B IgAN Peak Sales Upside
2M ago
VERA
Vera Therapeutics Adds Christopher Hite to Board
Premium
Company Announcements
Vera Therapeutics Adds Christopher Hite to Board
2M ago
8K
VERA
Vera Therapeutics appoints Hite to Board of Directors
PremiumThe Fly
Vera Therapeutics appoints Hite to Board of Directors
3M ago
VERA
3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026
PremiumMarket News
3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026
3M ago
UPB
VERA
Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright
PremiumThe Fly
Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright
3M ago
VERA
Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating
PremiumRatings
Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating
3M ago
VERA
Undervalued IgAN Opportunity: Buy Rating on VERA Driven by Atacicept’s Robust ORIGIN 3 Data and Long-Term Kidney Disease Upside
PremiumRatingsUndervalued IgAN Opportunity: Buy Rating on VERA Driven by Atacicept’s Robust ORIGIN 3 Data and Long-Term Kidney Disease Upside
3M ago
VERA
Vera Therapeutics: Buy Rating Backed by Strong Atacicept Data, Robust Cash Runway, and Large IgAN Market Opportunity
Premium
Ratings
Vera Therapeutics: Buy Rating Backed by Strong Atacicept Data, Robust Cash Runway, and Large IgAN Market Opportunity
3M ago
VERA
Vera Therapeutics reports FY25 EPS ($4.66), consensus ($4.44)
Premium
The Fly
Vera Therapeutics reports FY25 EPS ($4.66), consensus ($4.44)
3M ago
VERA
Vera Therapeutics sees cash runway through atacicept commercial launch
PremiumThe Fly
Vera Therapeutics sees cash runway through atacicept commercial launch
3M ago
VERA
Vera Therapeutics appoints Skelton as Chief Commercial Officer
PremiumThe Fly
Vera Therapeutics appoints Skelton as Chief Commercial Officer
4M ago
VERA
Buy Rating on Vera: De-Risked Atacicept Approval Path and Large IgA Nephropathy Market Drive Compelling Upside into 2026 Catalysts
PremiumRatings
Buy Rating on Vera: De-Risked Atacicept Approval Path and Large IgA Nephropathy Market Drive Compelling Upside into 2026 Catalysts
4M ago
VERA
Vera Therapeutics announces atacicept BLA accepted for Priority Review by FDA
PremiumThe Fly
Vera Therapeutics announces atacicept BLA accepted for Priority Review by FDA
4M ago
VERA
Wolfe upgrades Vertex Pharmaceuticals, says ‘may be due for a rebound’
PremiumThe FlyWolfe upgrades Vertex Pharmaceuticals, says ‘may be due for a rebound’
5M ago
VERA
VRTX
Short Report: Vera Therapeutics bears retreat as stock rallies
Premium
The Fly
Short Report: Vera Therapeutics bears retreat as stock rallies
5M ago
MBLY
MDGL
Vera Therapeutics price target raised to $66 from $48 at BofA
Premium
The Fly
Vera Therapeutics price target raised to $66 from $48 at BofA
5M ago
VERA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >